rand d

ISOPHOSPHAMIDE SHOWSPROMISE IN SOUD TUMOURS

Isophosphamide was given IV for at least four weeks to 52patients with advanced solid tumours; 4S patients Wereconsidered evaluable. Two drug regimens were followed,40mg/kg once a week, and 20mg/kg twice weekly.Of the 27 postmenopausalpatientswith metastatic breastcancer. 6 obtained no benefit from drug therapy and tumourprogression was not affected; 7 showed no substantial clinicalimprovement but there was no further tumour progression; 14demonstrated an objective response with two completeremissions lasting more than six months. Of the elevenevaluable patients with'lung cancer no response was obtainedin four cases of adenocarcinoma, objective responses were 215for epidermoid and 2/2 for oat-cell Carcinoma. Side-effectswere mild - alopecia 52 %', cystitis 37 %,'leukopenia 20 %,nausea 36 % , and mucositis 4 %. In this trial smaller doses ofisophosphamide were used than those reported by other

authors.Brema, F.et a!.: IRCS MedicalScience:Clinical Pharmacology andTherapeutics 5: 122(Apr 1977)

INPHARMA 30th April. 1977 p12